A Prospective Non-Interventional Study to Describe the Effectiveness and Safety of Venetoclax as a First-Line Treatment in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible to Intensive Chemotherapy in Routine Clinical Practice in Greece

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 20 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Venetoclax (Primary)
Indications Acute myeloid leukaemia
Focus Therapeutic Use
Acronyms SURVIVE
Sponsors AbbVie

Most Recent Events

26 Jan 2023 Planned primary completion date changed from 30 May 2026 to 31 Dec 2026.
25 Jan 2023 Planned primary completion date changed from 31 Dec 2026 to 30 May 2026.
11 Nov 2022 Planned primary completion date changed from 30 May 2026 to 31 Dec 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight